Recent

% | $
Quotes you view appear here for quick access.

Nokia Corporation Message Board

harleymark457 825 posts  |  Last Activity: Aug 27, 2016 12:01 AM Member since: Dec 14, 2012
  • Reply to

    BIG DUMP COMING....

    by littleplayer87 Aug 3, 2016 2:56 PM
    harleymark457 harleymark457 Aug 3, 2016 11:42 PM Flag

    Nah , that's just the prune you ate this morning when ya saw Gale go up.
    Just cover.. But your boss says keep posing.. Gotta make a living I gues .

  • harleymark457 by harleymark457 Aug 3, 2016 11:36 PM Flag

    Danny thinks so.. At my Gale usual prefix back slash www p something

  • harleymark457 harleymark457 Aug 3, 2016 8:02 PM Flag

    It better or I'm trailer my horse to their office and let her explode road apples on their lawn, yep

  • harleymark457 harleymark457 Aug 3, 2016 6:26 PM Flag

    Puts Gale $1.20-1.50. But day traders don't have time for that.. Donkey's

  • harleymark457 harleymark457 Aug 3, 2016 6:25 PM Flag

    Right ? I would think that if shorts shorted this far down, just cover and say it was good..
    Leaves things to the imagination . There boss says keep posting negative stuff.
    I do believe there is going to be a resolve meaning a rise in pps.
    Two orphan drug statice designations and perhaps findings of what the problem was with the
    Unusual request from IMDC . No shorts getting my shares , nope.

    Sentiment: Hold

  • Reply to

    No one is left

    by westflaguy Aug 2, 2016 4:17 PM
    harleymark457 harleymark457 Aug 2, 2016 9:41 PM Flag

    Don't flatter yourself soo much.. Funny how one feels his I.q.
    Is higher when one guesses correctly.. Shorts won the battle
    But not thewar.. There have been several bio's in the same spot.
    Ziop for one... Jazz.. I would hate to be barowing shares.. yep

  • Reply to

    No one is left

    by westflaguy Aug 2, 2016 4:17 PM
    harleymark457 harleymark457 Aug 2, 2016 7:26 PM Flag

    I jumped to conclusions , i always got the impression you were a short
    By some of the things you have posted .

  • Reply to

    No one is left

    by westflaguy Aug 2, 2016 4:17 PM
    harleymark457 harleymark457 Aug 2, 2016 7:19 PM Flag

    Wow good for you , profit 35k , hats off to ya.. Ya I still got a bag full of paper ..
    But at least I own them..golly if I shorted and made that much , I'd move on.. Yep

  • harleymark457 harleymark457 Aug 1, 2016 6:47 PM Flag

    This is a no brainier ! Buy.. Even if it takes a while.. Stay thirsty, go long.. Yep

  • harleymark457 harleymark457 Aug 1, 2016 6:45 PM Flag

    Better data than Cpxx had.. Yep, it had prolong life of 2-4 months.
    This one , 10-19 months prolong life.... And jazz bought Cpxx @ $30.00
    they didn't even have it on the market yet.. Same senecio forming here..
    Just sayin .. Glta.. I got lucky and got in at $1.44 this am.

    Sentiment: Buy

  • harleymark457 by harleymark457 Jul 31, 2016 10:15 PM Flag

    Adam Feuerstein's Biotech Blog
    Adam Feuerstein
    RSS Feed for Adam Feuerstein's Biotech Blog
    Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.
    To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form....
    .. Darn , there is a pic of him and he looks like j.c.'s kid .. Lmao!!!

  • Reply to

    NeuVax Story Far From Over

    by galetruth Jul 29, 2016 3:19 PM
    harleymark457 harleymark457 Jul 31, 2016 8:54 PM Flag

    Dang straight , two orphan drug Stacie . Still cooking..
    One fresh word from our captain (lor3d save us) bout
    Something found in IMDC request that lets them continue...wow 🚀
    Now that said, 2 'different' orphan drug go ahead in the pipe line ... 1.50
    IMHO .. Yep

    Sentiment: Buy

  • Reply to

    Good article

    by harleymark457 Jul 31, 2016 3:46 PM
    harleymark457 harleymark457 Jul 31, 2016 3:50 PM Flag

    Roche is generally regarded as the number one ophthalmology company in the world, and for a company the size of Eleven, is a dream partner.

    The IND acceptance triggered a payment of $22.5 million. As part of the agreement, if the IND got approved before September, Eleven stood to receive this $22.5 million all in one go. Since it’s July, it did. If the approval came after September, the company would have had to forego $2.5 million of the payment. If Roche had had to conduct extra animal studies before approval, the payment would reduce to $5 million, with $15 million pending until the FDA thumbs up.

    In short, it’s a best case scenario for Eleven.... Yep

    Sentiment: Buy

  • Reply to

    Good article

    by harleymark457 Jul 31, 2016 3:46 PM
    harleymark457 harleymark457 Jul 31, 2016 3:48 PM Flag

    We reckon there’s still plenty of room for gains. Here’s why.

    Eleven is a development stage biotech with one lead focus, an IL-6 inhibitor called EBI-031. It’s an ocular disease indication, and the company is currently investigating its efficacy in two focus conditions – Diabetic Macular Edema and Uveitis. The latter is the lead of the two targets right now. Uveitis is an inflammation of the uvea, which is the three layered part of the eye that contains the iris. When inflamed it can cause blurry vision, and eventually (if left untreated) blindness. IL-6 is a cytokine that is associated with the initiation of an inflammatory response – it’s already a target in things like rheumatoid arthritis and is under investigation as a potential oncology target. Anyway, in this instance, EBI-031 is an IL-6 inhibitor – it binds to the IL-6 receptors stopping the IL-6 cytokines from doing so, and in turn, stopping the inflammatory process from kicking off. That’s the theory, at least.

    So why all the bullish momentum as late? Well, the FDA just accepted what’s called an Investigational New Drug Application (IND) for the drug, which is a basically a green light for advancing the drug into human clinical trials. This is a pretty big step forward, but it wouldn’t normally bring with it gains to the tune of 1,000 percentage points. ......that is one reason for room higher , pps

    Sentiment: Buy

  • harleymark457 by harleymark457 Jul 31, 2016 3:46 PM Flag

    Eleven Biotherapeutics Inc (NASDAQ:EBIO): A Top Momentum Pick
    by MIKE ROBINSON | JULY 28, 2016..

  • Reply to

    Found this, didn't paste whole thing but .

    by harleymark457 Jul 30, 2016 4:48 PM
    harleymark457 harleymark457 Jul 30, 2016 4:57 PM Flag

    Sometimes companies do bounce back from failure

    Besides, there are other ways a company can recover from a so called "black swan" event. Look at Ziopharm, a company some suggest I love to hate.

    Back in 2013 Ziopharm had a Phase III trial failure with palifosfamide which sent shares of ZIOP crashing from up around $6 down to less than $2. A short two years later Ziopharm caught fire again and climbed to almost $15 in 2015 as investor excitement about the CAR T space sent shares bubbling with Ziopharm attaining a market cap in excess of $1.5 billion USD.

    Those that bought ZIOP in 2013 had the chance to realize gains of 500% or more if they played the contrarian game and bought the bad news of Ziopharm's trial failure. Perhaps those buying Galena around 40 to 50 cents currently will have a chance at similar gains in another year or two. ..

  • Reply to

    Found this, didn't paste whole thing but .

    by harleymark457 Jul 30, 2016 4:48 PM
    harleymark457 harleymark457 Jul 30, 2016 4:52 PM Flag

    The IDMC recommends that this be investigated as quickly as possible and, in the meantime, that this information be disclosed only to any individual(s) with a need to know about the procedures used to clarify the current situation. Finally, the DMC requests that Galena Biopharma inform the IDMC members of the outcome of this investigation and any decision with respect to discontinuation of the clinical trial as soon as possible.

    I don't want to read too much into the verbiage used, but it appears to me there is some "wiggle room" and that perhaps PRESENT could be re-started. However I consider that to be a faint hope and something that shareholders might cling onto even though it appears to me as ...

  • Calling all contrarians - Galena Biopharma worth a look
    by JOE RETAIL | JULY 30, 2016 ...

    Sentiment: Hold

  • harleymark457 harleymark457 Jul 28, 2016 5:05 PM Flag

    Roche will buy them before another milestone payment of 265 mill.
    And let Ebio get royalties from sales.. The will buy them before that happens.

    Sentiment: Strong Buy

  • harleymark457 harleymark457 Jul 28, 2016 4:49 PM Flag

    This mb hasn't moved in weeks. Yahoo havin probs. Takes me a while but it's a hassle.
    Go Ebio.. Quit selling .. Hold till $12-$16.. IMHO. Glta

NOK
5.67-0.07(-1.22%)Aug 31 4:04 PMEDT